On December 8, 2023, the news broke that no FC Barcelona fan wanted to hear. Mapi León was seriously injured in training and injured her meniscus. The Barça center-back, who had to undergo surgery, ...

Mapi León’s return to the Spanish women’s national team, three years after her last call-up, has been the biggest surprise in Sonia Bermúdez’s first squad announcement. The Barcelona defender says she ...

NESS ZIONA, Israel, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on developing innovative long-acting ...

Mapi Pharma has closed a $10 million (€9 million) Series A round to finance mid-phase trials of its once-a-month version of Teva's ($TEVA) blockbuster multiple ...

NESS ZIONA, Israel, March 31, 2022 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting ...

With the end of the year fast approaching, nations are looking for ways to secure enough supply of a potential COVID-19 vaccine to meet demand from their citizens. For Israeli drugmaker Mapi Pharma, ...

Mapi León, the last of ‘Las 15’ players who refused to play for the Spanish women’s national team in 2022 has returned to the fold this week after a three year absence. León last represented her ...

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ:ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that ...

Viatris likely just lost one of its top product debuts for 2024, thanks to an FDA rejection of its partner Mapi Pharma’s application for a new version of Teva’s multiple sclerosis (MS) drug Copaxone.

I run two separate Exchange environments for two different organizations. In both (Exchange 2010 and 2013, both fully patched to current), I get the occasion Event 9646 entry for clients that have ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.